TABLE 1.

Fimbrigal-P treatment modalities for rat oral candidiasis^a

Group (n) and treatment	Day
	1	2	3	4	5	6	7	8	9
Group 1: control group (15)
Cyclophosphamide 150 mg/kg i.p.	x
Candida inoculation		x	x	x
MC: 15, 10, 5; 5 rats for HP and TH						x		x	x
Group 2: preventative group (15)
Cyclophosphamide 150 mg/kg i.p.	x
Candida inoculation		x	x	x
Fimbrigal-P dose: 6.25 mg/250 μl twice a day		x	x	x
MC: 15, 10, 5; 5 rats for HP and TH						x		x	x
Group 3: drinking water group (15)
Cyclophosphamide 150 mg/kg i.p.	x
Candida inoculation		x	x	x
Fimbrigal-P dose: 0.5 mg/ml		x	x	x	x	x	x	x	x
MC: 15, 10, 5; 5 rats for HP and TH						x		x	x
Group 4: premixing group (15)
Cyclophosphamide 150 mg/kg i.p.	x
Candida inoculation: C. albicans 2 × 107 blastospores + 6.25 mg Fimbrigal-P in 200 μl normal saline		x	x	x
MC: 15, 10, 5; 5 rats for HP and TH						x		x	x
Group 5: treatment group (15)
Cyclophosphamide 150 mg/kg i.p.	x
Candida inoculation		x	x	x
Fimbrigal-P dose: 6.25 mg/250 μl orally twice a day				x	x	x
MC: 15, 10, 5; 5 rats for HP and TH						x		x	x

^aCandida inoculation for all groups: C. albicans 90028 (ATCC), 2 × 10⁷ blastospores/200 μl of normal saline orally. For groups 2 and 5, Fimbrigal-P (25 mg/ml in 0.4% of Carbopol Ex214) was administered at a dose of 250 μl/animal orally, using tuberculin syringes. For group 3, Fimbrigal-P was supplied in drinking water (0.5 mg/ml) from day 2 to the end of the experiment. For group 4, 100 μl Fimbrigal-P (50 mg/ml) was mixed with 2 × 10⁷ blastospores/100 μl of normal saline and then immediately administered orally to animals. In all test groups except group 3, the animals were supplemented orally with 0.1% tetracycline HCl for 1 week and then with 0.01% tetracycline until the end of the experiment. MC, microcurette sampling for fungal burden; TH, tongue homogenate fungal burden; HP, histopathology.